Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The BIO Ventures for Global Health AC3T initiative

AORTIC 2019 Conference

Published: 7 Feb 2020

Views: 2089

Rating:

Save

Jennifer Dent - CEO BIO Ventures for Global Health (BVGH), Seattle, USA

Jennifer Dent speaks to ecancer at the 2019 AORTIC conference in Maputo about the work of BIO Ventures for Global Health (BVGH).

In this video, she discusses AC3T (the African Consortium for Cancer Clinical Trails), which looks at the possibility to conduct cancer clinical trials at 25 hospitals across Africa.

Jennifer outlines why this representation in clinical trails is important, and which countries will be involved.

Related Videos

Perspectives on advance care planning for advanced cancer in the Philippines

Dr Sachiko Estreller - Cordillera Hospital of the Divine Grace, Benguet...

Perspectives on advance care planning for advanced cancer in the Philippines ( Dr Sachiko Estreller - Cordillera Hospital of the Divine Grace, Benguet, Philippines )

Grand Rounds: Improving quality of patient-centred care

Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado

Grand Rounds: Improving quality of patient-centred care ( Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado )

Choosing Wisely conferences: Lessons learned and the way forward

Dr Omar Abdihamid - Garissa Cancer Centre, Garissa, Kenya

Choosing Wisely conferences: Lessons learned and the way forward ( Dr Omar Abdihamid - Garissa Cancer Centre, Garissa, Kenya )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India

Lung Cancer ( Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC

Dr Stephen Chun - MD Anderson, Houston, USA

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC ( Dr Stephen Chun - MD Anderson, Houston, USA )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

More from ecancer